Screener
Amneal Pharmaceuticals, Inc. AMRX Specialty — In-licensing and upfront milestones
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Amneal Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept amrx:InLicensingAndUpfrontMilestones.
The source filing: Amneal Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 5:19 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001723128-26-000031
| Line item | Three Months Ended June 30, 2026 / Affordable Medicines | Three Months Ended June 30, 2026 / Specialty | Three Months Ended June 30, 2025 / Affordable Medicines | Three Months Ended June 30, 2025 / Specialty |
|---|---|---|---|---|
| Employee compensation and benefits | $12,016 | $1,326 | $14,693 | $1,279 |
| Materials and supplies | 8,796 | 1,022 | 8,108 | 450 |
| Product development and studies (1) | (89) | 2,615 | 756 | 2,371 |
| In-licensing and upfront milestones | 3,500 | — | 6,350 | — |
| Facilities costs | 1,479 | 30 | 1,793 | 735 |
| Regulatory fees | 1,334 | — | 2,932 | — |
| Other (2) | 5,987 | 1,001 | 7,267 | 1,230 |
| Total | $33,023 | $5,994 | $41,899 | $6,065 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Amneal Pharmaceuticals, Inc.'s specialty — in-licensing and upfront milestones?
- Amneal Pharmaceuticals, Inc. (AMRX) reported specialty — in-licensing and upfront milestones of $0 in Q2 2026.
- What does specialty — in-licensing and upfront milestones mean?
- This metric represents the financial obligations or expenditures related to acquiring rights to proprietary pharmaceutical products through external licensing agreements. It captures the initial payments and milestone-based fees paid to partners to secure access to specialty drug pipelines or commercialized assets. Monitoring this figure provides insight into the company's strategy for expanding its branded portfolio and the capital intensity required to fuel long-term growth in the specialty therapeutics market.
Ask your AI about Amneal Pharmaceuticals, Inc.'s specialty — in-licensing and upfront milestones.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude